# Bain Capital Life Sciences Investors, 13F Q2 2026

Bain Capital Life Sciences Investors, LLC reported $1.7 billion in 13F securities across 21 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Kailera Therapeutics Inc at $498 million, 29.6% of the reported value. Since Q1 2026 it opened 2 new positions and exited 1.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,682,021,456
- Positions: 21
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1703031
- Form 13F file number: 028-18477
- Business address: 200 Clarendon Street, Boston, MA 02116
- SEC filing: [0001193125-26-350470](https://www.sec.gov/Archives/edgar/data/1703031/000119312526350470/0001193125-26-350470-index.htm)

## Top 21 holdings by value

The largest of 21 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 22,583,268 | $497.5 million | New |
| [Heartflow Inc](https://specstream.ai/data/institutional-holders/heartflow-inc-42238d107) | COM | 8,448,158 | $247.9 million | -2,000,000 |
| [Newamsterdam Pharma Company](https://specstream.ai/data/institutional-holders/newamsterdam-pharma-company-n62509109) | ORDINARY SHARES | 3,806,566 | $129 million | -3,500,000 |
| [Savara Inc](https://specstream.ai/data/institutional-holders/savara-inc-805111101) | COM | 17,600,621 | $108.4 million | No change |
| [Alkermes PLC](https://specstream.ai/data/institutional-holders/alkermes-plc-g01767105) | SHS | 1,937,938 | $101.5 million | +1,327,938 |
| [Solid Biosciences Inc](https://specstream.ai/data/institutional-holders/solid-biosciences-inc-83422e204) | COM NEW | 9,808,819 | $98 million | No change |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 2,675,509 | $92.5 million | No change |
| [Olema Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/olema-pharmaceuticals-inc-68062p106) | COM | 7,085,249 | $88.6 million | -387,989 |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 1,650,000 | $60.6 million | New |
| [Cabaletta Bio Inc](https://specstream.ai/data/institutional-holders/cabaletta-bio-inc-12674w109) | COM | 17,241,445 | $53.6 million | +7,564,320 |
| [X4 Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/x4-pharmaceuticals-inc-98420x202) | COM NEW | 7,967,454 | $37.2 million | No change |
| [Dianthus Therapeutics Inc](https://specstream.ai/data/institutional-holders/dianthus-therapeutics-inc-252828108) | COM | 362,470 | $35.3 million | No change |
| [C4 Therapeutics Inc](https://specstream.ai/data/institutional-holders/c4-therapeutics-inc-12529r107) | COM STK | 7,171,910 | $33.5 million | No change |
| [Kyverna Therapeutics Inc](https://specstream.ai/data/institutional-holders/kyverna-therapeutics-inc-501976104) | COM | 2,885,000 | $25.7 million | -225,000 |
| [Annexon Inc](https://specstream.ai/data/institutional-holders/annexon-inc-03589w102) | COM | 4,437,731 | $25.3 million | -774,943 |
| [Rapid Micro Biosystems Inc](https://specstream.ai/data/institutional-holders/rapid-micro-biosystems-inc-75340l104) | CLASS A COM | 8,434,560 | $14.6 million | No change |
| [Disc Medicine Inc](https://specstream.ai/data/institutional-holders/disc-medicine-inc-254604101) | COM | 141,234 | $10.3 million | No change |
| [Atea Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/atea-pharmaceuticals-inc-04683r106) | COM | 2,075,639 | $9.7 million | -284,999 |
| [Xilio Therapeutics Inc](https://specstream.ai/data/institutional-holders/xilio-therapeutics-inc-98422t209) | COM | 664,021 | $6.4 million | No change |
| [Upstream Bio Inc](https://specstream.ai/data/institutional-holders/upstream-bio-inc-91678a107) | COM | 600,949 | $4.2 million | -266,262 |
| Newamsterdam Pharma Company | \*W EXP 99/99/999 | 99,999 | $2.1 million | No change |

## New positions in Q2 2026

2 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Kailera Therapeutics Inc](https://specstream.ai/data/institutional-holders/kailera-therapeutics-inc-482931102) | COMMON STOCK | 22,583,268 | $497.5 million |
| [Hemab Therapeutics Hldgs Inc](https://specstream.ai/data/institutional-holders/hemab-therapeutics-hldgs-inc-423494103) | COM SHS | 1,650,000 | $60.6 million |

## Positions exited in Q2 2026

1 position in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Centessa Pharmaceuticals PLC | SPONSORED ADS | 635,000 | $25.2 million |

## Also on SpecStream

- [Bain Capital Life Sciences Investors, LLC Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1703031/000119312526350470/0001193125-26-350470-index.htm)
- [Largest 13F filers in Massachusetts](https://specstream.ai/data/institutional-holdings/state/massachusetts)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Boston, Massachusetts

- [Divorce and family law firms in Boston, Massachusetts](https://specstream.ai/data/businesses/divorce-and-family-law-firms/boston-massachusetts-united-states)
- [Outpatient care facilities in Boston, Massachusetts](https://specstream.ai/data/businesses/outpatient-care-facilities/boston-massachusetts-united-states)
- [Biotechnology companies in Boston, Massachusetts](https://specstream.ai/data/businesses/biotechnology-companies/boston-massachusetts-united-states)
- [Internet marketing agencies in Boston, Massachusetts](https://specstream.ai/data/businesses/internet-marketing-agencies/boston-massachusetts-united-states)
- [Software development companies in Boston, Massachusetts](https://specstream.ai/data/businesses/software-development-companies/boston-massachusetts-united-states)
- [Education services in Boston, Massachusetts](https://specstream.ai/data/businesses/education-services/boston-massachusetts-united-states)
